A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) plus Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Gastric Cancer (FRACTION-Gastric Cancer)
A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer
An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
A prospective, multinational, multi-center, phase 2, randomized, controlled, open-label study evaluating the efficacy, safety, tolerability and pharmacokinetics of sig12d-loder in the treatment of patients with unresectable locally advanced pancreatic cancer when used in conjunction with standard chemotherapy (gemcitabine+nab-paclitaxel) versus chemotherapy (gemcitabine+nab-paclitaxel) alone
A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) plus Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma
![Alert Sign](https://www.hackensackumc.org/wp-content/themes/hackensack-umc/images/exclamation-triangle.svg")
![Close Alert Box](https://www.hackensackumc.org/wp-content/themes/hackensack-umc/images/X.svg")
